α-(3,4-dimethyoxyphenyl)-3,4-dihydro6-7-dimethoxy-α[(4- methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): A novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A

Oncology Research

Volumn 8, Issue 5, 1996, Pages 207-218

  Greenberger, Lee M ^a   Collins, Karen I ^a   Annable, Tami ^a   Boni, Joseph P ^a   May, Michael K ^b   Lai, Fong M ^a   Kramer, Robert ^a   Citeralla, Ronald V ^a   Hallett, William A ^a   Powell, Dennis ^a  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

CL 329,753; cyclosporine; drug resistance; P glycoprotein; verapamil

Indexed keywords

BISANTRENE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CL 329753; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; PLACEBO; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIZATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029796991     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. 1. Young, R. C. Drug resistance: the clinical problem. In: Ozols, R. F., ed. Drug resistance in cancer therapy. Boston: Kluwer Academic Press; 1989:pp. 1-12.
2. 2. Pratt, W. B. Drug resistance. In: Pratt, W. B.; Taylor, P., eds. Principles of drug action. The basis of pharmacology. New York: Churchill Livingstone; 1990:pp. 565-638.
3. 3. Greenberger, L. M.; Cohen, D.; Horwitz, S. B. In vitro models of multiple drug resistance. In: Ozols, R. F.; Goldstein, L. J., eds. Anticancer drug resistance. Boston: Kluwer Academic Publishers; 1994:pp. 69-106.
4. 4. Arceci, R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-2222; 1993.
5. 5. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427; 1993.
6. 6. Grant, C. E.; Valdimarsson, G.; Hipfner, D. R.; Almquist, K. C.; Cole, S. P. C.; Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases in resistance to natural products. Cancer Res. 54: 357-361; 1994.
7. 7. Zaman, G. J. R.; Flens, M. J.; van Leusden, M. R.; de Haas, M.; Mulder, H. S.; Lankelma, J.; Pinedo, H. M.; Scheper, R. J.; Baas, F.; Broxterman, H. J.; Borst, P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91:8822-8826; 1994.
8. 8. Greenberger, L. M.; Ishikawa, Y. ATP-binding cassette proteins: common denominators between ion channels, transporters, and enzymes. Trends Cardiovas. Med. 4:41-46; 1994.
9. 9. Goldstein, L. J.; Galski, H.; Fojo, A.; Willingham, M.; Lai, S. L.; Gazdar, A.; Pirker, R.; Cossman, J.; Gottesman, M. M.; Pastan. I. Expression of multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81:116-124; 1989.
10. 10. Yang, C.; Greenberger, L. M.; Horwitz, S. B. Reversal of multidrug resistance in tumor cells. In: Chou, T. C.; Rideout, D. C., eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press; 1991:pp. 311-338.
11. 11. Sikic, B. I.; Fisher, G. A.; Lum, B. L.; Brophy, N. A.; Yahanda, A. M.; Adler, K. M.; Halsey, J. Clinical reversal of multidrug resistance. In: Ozols, R. F.; Goldstein, L. J., eds. Anticancer drug resistance. Boston: Kluwer Academic Publishers; 1994:pp. 149-165.
12. 12. Gruber, A.; Peterson, C.; Reizenstein, P. D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int. J. Cancer 41: 224-226; 1988.
13. 13. Eliason, J. F.; Ramuz, H.; Kaufmann, F. Human multidrug resistant cancer cells exhibit a high degree of selectivity for stereoisomers of verapamil and quinidine. Int. J. Cancer 46:113-117; 1990.
14. 14. Boesch, D.; Gaveriaux, C.; Jachnes, B.; Poutier-Manzanedo, A.; Bollinger, P.; Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumors with SDZ PSC 833. Cancer Res. 51:4226-4233; 1991.
15. 15. Zhang, X. P.; Ritke, M. K.; Yalowich, J. C.; Slovak, M. L.; Ho, J. P.; Collins, K. I.; Annable, T.; Arceci, R. J.; Greenberger, L. M. P-glycoprotein mediates profound resistance to bisantrene. Oncol. Res. 6:291-301; 1994.
16. 16. Shen, D.-W.; Cardarelli, C.; Hwang, J.; Cornwell, M.; Richert, N.; Ishii, S.-I.; Pastan, I.; Gottesman, M. M. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 261:7762-7770; 1986.
17. 17. Zhang, X. P.; Collins, K. I.; Greenberger, L. M. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug binding pore in P-glycoprotein encoded by MDR1. J. Biol, Chem. 270:5441-5448; 1995.
18. 18. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112; 1990.
19. 19. Lowry, O. H.; Rosenbrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with folin phenol reagent. J. Biol Chem. 193:265-275; 1951.
20. 20. Cornwell, M. M.; Gottesman, M. M.; Pastan, I. H. Increased vinblastine binding to membrane vesicles from multidrug resistant KB cells. J, Biol. Chem. 261: 7921-7928; 1986.
21. 21. Lai, F. M.; Cobuzzi, A.; Tanikella, T.; Cervoni, P. Relaxant actions of viprostol and prostaglandin E2 on tracheal muscle and their effects on calcium influx. Prostaglandins 36:115-123; 1988.
22. 22. Jacquet, J. M.; Galtier, M.; Bressolle, F.; Jourdan, J. A sensitive and reproducible HPLC assay for doxorubicin and pirarubicin. J. Pharm. Biomed. Anal. 10:343-349; 1992.
23. 23. Rose, L. M.; Tillery, K. F.; El Dareer, S. M.; Hill, D. L. High-performance liquid Chromatographic determination of doxorubicin and its metabolites in plasma and tissue. J. Chromatography 425:419-423; 1988.
24. 24. Gibaldi, M.; Perrier, D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc.; 1982:pp. 445-449.
25. 25. Bailer, A. J. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 16:303-309; 1988.
26. 26. Vanhoefer, U.; Cao, S.; Minderman, H.; Toth, K.; Scheper, R. J.; Slovak, M. L.; Rustum, Y. M. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin. Cancer Res. 2:369-377; 1995.
27. 27. Colombo, T.; Zucchetti, M.; D'Incalci, M. Cyclosporine A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp. Therap. 269:22-27; 1994.
28. 28. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972; 1981.
29. 29. Saeki, T.; Udea, K.; Tanigawara, Y.; Hori, R.; Komano, T. Human P-glycoprotein transports cyclosporine and FK506. J. Biol. Chem. 268:6077-6080; 1993.
30. 30. Archinal-Matthies, A.; Rzepka, R. W.; Watanabe, T.; Kokubu, N.; Itoh, Y.; Combates, N. J.; Bair, K. W.; Cohen, D. Analysis of the interaction of SDZ PSC 833 ([[3′-keto-Bmt-1]Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res. 7:603-610; 1995.
31. 31. Cano-Gauci, D. F.; Riordan, J. R. Action of calcium channel antagonists on multidrug resistant cells: specific cytotoxicity independent of increased cancer drug accumulation. Biochem. Pharmacol. 36:2115-2123; 1987.
32. 32. Tamai, I.; Safa, A. R. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 266:16796-16800; 1991.
33. 33. Tamai, I.; Safa, A. R. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265:16509-16513; 1990.
34. 34. Kajiji, S.; Talbot, F.; Grizzuti, K.; Van Dyke-Phillips, V.; Agresti, M.; Safa, A. R.; Gros, P. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry 32:4185-4194; 1993.
35. 35. Cardarelli, C. O.; Aksentijevich, I.; Pastan, I.; Gottesman, M. M. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res. 55:1086-1091; 1995.
36. 36. Toffoli, G.; Simone, F.; Corona, G.; Raschack, M.; Cappelletto, B.; Gigante, M.; Boiocchi, M. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem. Pharmacol. 50: 1245-1255; 1995.
37. 37. Miller, T. P.; Grogan, T. M.; Dalton, W. S.; Spier, C. M.; Scheper, R. J.; Salmon, S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9:17-24; 1991.
38. 38. Horton, J. K.; Thimmaiah, K. N.; Houghton, J. A.; Horowitz, M. E.; Houghton, P. J. Modulation of verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem. Pharmacol. 38:1727-1736; 1989.
39. 39. Hyafil, F.; Vergely, C.; Vinnaud, P. D.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602; 1993.
40. 40. Schinkel, A. H.; Smit, J. J. M.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van der Deemter, L.; Mol, C. A. A. M.; van der Valk, M. A.; Robanus-Manndag, E. C.; te Riele, H. P. J.; Berns, A. J. M.; Borst, P. Disruption of the mouse mdrIa P-glycoprotein leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502; 1994.
41. 41. Zamora, J. M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454-462; 1988.
42. 42. Webster, L.; Linsenmeyer, M.; Millward, M.; Morton, C.; Bishop, J.; Woodcock, D. Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug resistance phenotype. J. Natl. Cancer Inst. 85: 1685-1690; 1993.
43. 43. Woodcock, D. M.; Jefferson, S.; Linsenmeyer, M. E.; Crowther, P. J.; Chojnowski, G. M.; Williams, B.; Bertoncello, I. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:4199-4203; 1990.